In my first article, I talked about Novavax's (NVAX) revolutionary rapid formula VLP technology, a process that reduces the timeline to produce an effective vaccine by up to 83%. And in my most recent article, I addressed the proposed acquisition of adjuvant maker Isconova and expressed some reservations about the real motivations behind that move. Those apprehensions had to do with safety data from the RSV Phase 1 trial in the elderly. Novavax has responded.
A scant three days later, top-line results were revealed. And what the numbers suggest is that the acquisition of Isconova has nothing to do with tolerability data in either RSV trial. It may have to do with having tax write-offs for weekend...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: